Cite
HARVARD Citation
Ducassou, S. et al. (2017). Benefits of rituximab as a second‐line treatment for autoimmune haemolytic anaemia in children: a prospective French cohort study. British journal of haematology. pp. 751-758. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Ducassou, S. et al. (2017). Benefits of rituximab as a second‐line treatment for autoimmune haemolytic anaemia in children: a prospective French cohort study. British journal of haematology. pp. 751-758. [Online].